

| Session | Theme                              | 20 September |             | 21 September |             |             |             | 22 September |             |             |             | 23 September |             |
|---------|------------------------------------|--------------|-------------|--------------|-------------|-------------|-------------|--------------|-------------|-------------|-------------|--------------|-------------|
|         |                                    | 13:45-15:15  | 16:00-17:30 | 09:00-10:30  | 11:00-12:30 | 13:30-15:00 | 15:30-17:00 | 09:00-10:30  | 11:00-12:30 | 13:30-15:00 | 15:30-17:00 | 09:00-10:30  | 11:00-12:30 |
| 1.1     | Multi-Organ-Chip I                 |              |             | ■            |             |             |             |              |             |             |             |              |             |
| 1.2     | Multi-Organ-Chip II                |              |             |              |             |             | ■           |              |             |             |             |              |             |
| 2       | Stem Cells                         |              |             | ■            |             |             |             |              |             |             |             |              |             |
| 3.1     | 3D Models I                        |              | ■           |              |             |             |             |              |             |             |             |              |             |
| 3.2     | 3D Models II                       |              |             |              |             |             |             |              |             | ■           |             |              |             |
| 4       | 3R International                   |              |             |              |             | ■           |             |              |             |             |             |              |             |
| 5.1     | QSAR & Read Across I               |              |             |              |             |             |             |              |             | ■           |             |              |             |
| 5.2     | QSAR & Read Across II              |              |             |              | ■           |             |             |              |             |             |             |              |             |
| 6       | Risk Ass. & AOP                    |              |             |              |             | ■           |             |              |             |             |             |              |             |
| 7       | Rep. Dose & Other Endpoints        |              |             |              |             |             |             |              | ■           |             |             |              |             |
| 8       | Inhalation                         |              |             |              |             |             |             |              |             | ■           |             |              |             |
| 9.1     | Skin Sensitization I               | ■            |             |              |             |             |             |              |             |             |             |              |             |
| 9.2     | Skin Sensitization II              |              |             |              |             |             |             |              | ■           |             |             |              |             |
| 10.1    | Efficacy & Safety Testing I        |              |             |              |             |             |             | ■            |             |             |             |              |             |
| 10.2    | Efficacy & Safety Testing II       |              |             | ■            |             |             |             |              |             |             |             |              |             |
| 11      | Nano-Toxicology                    |              |             |              | ■           |             |             |              |             |             |             |              |             |
| 12.1    | Disease Models I: CRISPR/cas       |              | ■           |              |             |             |             |              |             |             |             |              |             |
| 12.2    | Disease Models II: hiPSC           |              |             |              | ■           |             |             |              |             |             |             |              |             |
| 12.3    | Disease Models III: Inflammation   |              |             |              |             |             |             |              |             |             |             | ■            |             |
| 13      | Biobarriers                        |              |             |              |             |             |             |              |             |             |             |              | ■           |
| 14      | Directive 2010/63/EU               |              |             |              |             | ■           |             |              |             |             |             |              |             |
| 15.1    | Ethics & Legal Issues I            |              |             |              |             |             | ■           |              |             |             |             |              |             |
| 15.2    | Ethics & Legal Issues II           |              |             |              |             |             |             | ■            |             |             |             |              |             |
| 16.1    | Refinement I and Culture of Care   |              |             |              |             |             |             |              |             |             | ■           |              |             |
| 16.2    | Refinement II                      |              |             |              |             |             |             |              | ■           |             |             |              |             |
| 17.1    | Replacement I                      |              |             |              |             |             |             | ■            |             |             |             |              |             |
| 17.2    | Replacement II                     |              |             |              |             |             |             |              |             |             | ■           |              |             |
| 18.1    | 3Rs in Academia & Education I      | ■            |             |              |             |             |             |              |             |             |             |              |             |
| 18.2    | 3Rs in Academia & Education II     |              |             |              |             |             | ■           |              |             |             |             |              |             |
| 19.1    | Young Scientists Short Lectures I  |              |             |              |             |             |             |              |             |             | ■           |              |             |
| 19.2    | Young Scientists Short Lectures II |              |             |              |             |             |             |              |             |             |             |              | ■           |